Explore the world of biopharmaceuticals: learn about the processes behind industry innovation and how they improve patients' lives every day.
In the age of personalized medicine, biomarkers are emerging as important tools in drug development.
A well-defined regulatory pathway for biomarker qualification can help improve our understanding of drug development, accelerate patient access to promising therapies, open new avenues for research and yield a more competitive and sustainable biopharmaceutical ecosystem.
Early and consistent treatment is crucial to successful management of multiple sclerosis (MS). Therapeutic advances over the past decade have offered patients more convenient options with fewer side effects, leading to improved treatment outcomes.
Immuno-oncology is based on the concept of harnessing the body’s own immune system to fight cancer, and recent scientific discoveries and clinical advances have ushered in a truly historical time in cancer research.
Dr. Tim Garnett, chief medical officer at Eli Lilly and Company underscores that developing innovative, lifesaving medicines for patients is the sole focus of the biopharmaceutical industry.
Research on a medicine doesn’t end on the initial approval by the FDA. Eli Lilly and Company’s chief medical officer shares why ongoing research helps us better understand a medicines full value.
ADCs more accurately attack specific targets fueling cancer cell growth while leaving more healthy cells unharmed.
Expanded treatment options over the past decade have reduced barriers to patient compliance and helped patients better manage diabetes and enjoy a better quality of life.
The introduction of statin therapy nearly 30 years ago transformed the treatment of high cholesterol for many patients, yet some continued to face challenges. Advances over the past decade have provided important treatment options for these patients.
According to new analysis released from the Personalized Medicine Coalition, 2015 was a record year for personalized medicine approvals.
Rapid pace of science propels important treatment advances for patients in 2015
From drug discovery through FDA approval, developing a new medicine takes at least 10 years on average and costs an average of $2.6 billion.
Advancements in science and technology are changing the way we study disease, develop drugs and prescribe treatments
America’s innovative biopharmaceutical companies are at the heart of a dynamic ecosystem.
42% of medicines in the pipeline are personalized medicines
Emerging Science Fuels New Treatment Advances for Patients
Growing Scientific Understanding Drives Transformative Advances in Treatment
New Era of Targeted Therapy Shift Treatment Paradigm
Clinical trials are central to the work of biopharmaceutical researchers - they advance the science of bringing new medicines to the patients who need them.
Recent Advances Attack Both the Symptoms and Cause of the Disease
Therapeutic Advances Slow Disease Progression and Keep Patients Active
Find out what made 2014 a great year for new medicine approvals.
The introduction of HAART treatments caused a significant drop in the HIV/AIDS death rate.
Before medical innovation dramatically increased the survival rate of HIV/AIDS, many worried that the fatal infection would bankrupt the health care system.
Between 1998 and 2014, there were 75 unsuccessful drugs and 3 approved drugs for brain cancer.
Between 1998 and 2014, there were 96 unsuccessful drugs and 7 approved drugs for melanoma.
Between 1998 and 2014, there were 167 unsuccessful drugs and 10 approved drugs for lung cancer.
New medicines, including combination treatments for HIV/AIDS, have transformed what was once a fatal diagnosis into a chronic disease for many patients.
For decades, the U.S. biopharmaceutical industry has led the world in the discovery and development of new medicines. Will it stay that way?
Cancer is a heavy burden for patients as well as the economy. Find out how research is helping.
The 5-year survival rate for chronic myeloid leukemia (CML) patients has increased dramatically since imatinib was first approved for treatment in 2001.
Where do generic drugs come from? Medicines have a long lifecycle from research to brand name drug to generic form. Over time, innovation leads to increased competition on price and clinical effects.
Innovative treatments have transformed the way we attack many devastating diseases. Learn more about the key advances that have changed medicine over the last century.
Meet inspiring individuals who were diagnosed with a serious medical condition and learn how advanced medical technology helps them lead healthy lives once again.
Advances in treating debilitating diseases are often not the result of one single breakthrough, but rather an accumulation of knowledge and research over time.
New and forthcoming medicines can halt the progression of hepatitis C and, in many cases, provide a cure.
View stories from scientists and researchers working in drug discovery and development at America’s biopharmaceutical companies.